Source comparison
TB-500 for Meniscus Injury: Research vs Clinical Reality Comparison
Dosing precision 2–2.5mg exactly measured, pharma-grade peptide, verified potency Variable peptide purity, reconstitution errors common, dosing often eyeballed Quality of peptide source matters more than minor dosing variations. Impure peptide at 'correct' dos
This comparison does not assign a generated winner or score.
- Dosing precision
- 2–2.5mg exactly measured, pharma-grade peptide, verified potency
- Variable peptide purity, reconstitution errors common, dosing often eyeballed
- Quality of peptide source matters more than minor dosing variations. Impure peptide at 'correct' dose achieves nothing
- Injection timing
- Twice weekly at exact 72-hour intervals, controlled for circadian timing
- Patients inject when convenient, intervals vary 60–96 hours
- Consistency matters more than precision. 3–4 day intervals work, erratic timing doesn't
- Activity restriction
- Structured progressive loading with biomechanical monitoring
- Patients often return to activity based on pain reduction, not tissue healing timeline
- This is where most protocols fail. Symptom improvement precedes structural repair by 6–10 weeks
- Outcome measurement
- MRI signal changes, histological analysis, biomechanical testing
- Subjective pain scores, return-to-activity timelines
- Patient-reported outcomes improve faster than imaging changes. Managing expectations prevents premature loading
- Combination therapies
- TB-500 monotherapy to isolate effects
- Often combined with BPC-157, GH peptides, NSAIDs
- Synergistic combinations likely work better than isolated peptides, but complicate attribution of results